Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Solid Biosciences Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Solid Biosciences Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Smith Ian F | Director | 138,145 | Jul 7, 2026 | 5 |
| Edelman Joseph | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Advisors LLC | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Perceptive Life Sciences Master Fund Ltd | Director, 10% Owner | 11,833,539Indirect | Jun 11, 2026 | 2 |
| Nagendran Sukumar | Director | – | Jun 11, 2026 | 1 |
| Freed Martin I | Director | – | Jun 11, 2026 | 1 |
| Stone Adam Leo | Director | – | Jun 11, 2026 | 1 |
| Ganot Ilan | Director | 27,474Indirect | Jun 11, 2026 | 7 |
| Sullivan Lynne Marie | Director | – | Jun 11, 2026 | 1 |
| Keresty Georgia | Director | – | Jun 11, 2026 | 1 |
| Kahn Clare | Director | 2,960 | Jun 11, 2026 | 1 |
| Howton David T | Chief Operating Officer | 105,077 | Apr 21, 2026 | 5 |
| Cumbo Alexander | President and CEO | 235,405 | Apr 21, 2026 | 5 |
| Tan Kevin | CFO & Treasurer | 99,422 | Apr 21, 2026 | 5 |
| Hanrahan Jessie | Chief Regulatory Officer | 74,318 | Apr 21, 2026 | 5 |
| Herzich Paul | Chief Technology Officer | 72,638 | Apr 21, 2026 | 5 |
| Brooks Gabriel | Chief Medical Officer | 89,466 | Apr 21, 2026 | 5 |
| BCIP Life Sciences Associates, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Partners, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS SB Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Fund II, L.P. | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Bain Capital Life Sciences Investors II, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco, LP | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Investco (GP), LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| BCLS II Equity Opportunities GP, LLC | 10% Owner | 5,034,582Indirect | Feb 21, 2025 | 0 |
| Perceptive Xontogeny Venture Fund, LP | Director, 10% Owner | 11,833,539Indirect | Feb 21, 2025 | 0 |
| RA Capital Healthcare Fund LP | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Ra Capital Management, L.P. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Kolchinsky Peter | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Shah Rajeev M. | 10% Owner | 4,192,216Indirect | Feb 21, 2025 | 0 |
| Atchinson Robert | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Gross Phillip | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Adage Capital Management, L.P. | 10% Owner | 4,248,084Indirect | Feb 19, 2025 | 0 |
| Marlowe Jennifer | CSO | 6,998 | Feb 16, 2024 | 0 |
| RA Capital Nexus Fund, L.P. | Director, 10% Owner | 4,192,216Indirect | Jan 12, 2024 | 0 |
| Koppel Adam | Director, 10% Owner | 4,034,582Indirect | Jan 12, 2024 | 0 |
| Morris Carl Ashley | Chief Scientific Officer | 19,760 | Jan 31, 2023 | 0 |
| Huffines Robert Luther | Director | – | Dec 15, 2022 | 0 |
| Perceptive Venture Advisors, LLC | Director, 10% Owner | 73,107Indirect | Dec 6, 2022 | 0 |
| Brennan Erin Powers | Chief Legal Officer, Secretary | – | May 4, 2022 | 0 |
| Schneider Joel Solomon Zev | Chief Operating Officer | 236,270 | Mar 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Howton David TChief Operating Officer | SSale | −37.8K | $6.44 | −$243.2K | −24.4%116.8K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Brooks GabrielChief Medical Officer | SSale | −28.3K | $6.44 | −$182.5K | −22.7%96.7K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −26.5K | $6.44 | −$170.9K | −24.3%82.7K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Cumbo AlexanderPresident and CEO | SSale | −80.3K | $6.44 | −$516.9K | −22.9%270.9K after | 10b5-1 |
| Feb 2, 2026 (view filing) | Feb 2 | Same day | Tan KevinCFO & Treasurer | SSale | −26.8K | $6.44 | −$172.8K | −19.8%109.0K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Herzich PaulChief Technology Officer | SSale | −10.9K | $6.44 | −$70.2K | −13.6%69.1K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Hanrahan JessieChief Regulatory Officer | SSale | −12.3K | $6.44 | −$79.5K | −14.9%70.3K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Brooks GabrielChief Medical Officer | SSale | −12.6K | $6.44 | −$81.2K | −13.0%84.1K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Tan KevinCFO & Treasurer | SSale | −14.8K | $6.44 | −$95.2K | −13.6%94.2K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Ganot IlanDirector | SSale | −7.21K | $6.44 | −$46.4K | −22.2%25.3K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Cumbo AlexanderPresident and CEO | SSale | −48.9K | $6.44 | −$315.0K | −18.1%222.0K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Howton David TChief Operating Officer | SSale | −18.9K | $6.44 | −$121.7K | −16.2%97.9K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Tan KevinCFO & Treasurer | SSale | −5.40K | $5.82 | −$31.5K | −5.2%99.4K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Brooks GabrielChief Medical Officer | SSale | 0 | – | $0 | 0.0%89.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Howton David TChief Operating Officer | SSale | −7.47K | $5.82 | −$43.5K | −6.6%105.1K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Herzich PaulChief Technology Officer | SSale | −3.62K | $5.82 | −$21.0K | −4.7%72.6K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Ganot IlanDirector | SSale | −2.66K | $5.82 | −$15.5K | −8.8%27.5K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Hanrahan JessieChief Regulatory Officer | SSale | −4.13K | $5.82 | −$24.1K | −5.3%74.3K after | 10b5-1 |
| Feb 18, 2026 (view filing) | Feb 18 | Same day | Cumbo AlexanderPresident and CEO | SSale | −16.6K | $5.82 | −$96.9K | −6.6%235.4K after | 10b5-1 |